Quantcast Amdl Signs Distribution Deal
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

Amdl Signs Distribution Deal

Posted on 10/12/2007 14:54 PM | Link | Post Comment
by Richard Daverman, PhD
ChinaBio Today



AMDL, Inc. (ADL) reported that its China subsidiary, Jade Pharmaceutical, signed on Heze Mudan Medicals Co. Ltd. to distribute Jade’s Domperidone tablets, a drug used to treat nausea and vomiting. Jade’s generic version of Domperidone is less expensive than its competitors.

The agreement covers the Province of Shangdong, one of the more affluent regions in China. Heze Mudan has promised to provide a minimum level of revenue, and Jade said it expects the arrangement to add at least $2.3 million annually to sales.

In the second quarter of 2007, AMDL had revenues of just $2.4 million ($800,000 per month), so the additional $2.3 million annually is significant to the company. Even without the new distribution deal, AMDL is growing quickly. The $2.4 million second quarter was a 69% improvement over the first quarter of 2007.

Frank Zheng, managing director of Jade Pharmaceutical, expects the company to book $24 million in sales during the coming 12 months. Gary Dreher, CEO of AMDL, said he expects annual sales to hit a level of $100 million in the next four to five years.

AMDL has 12.6 million shares outstanding. At its present share price of $4.33, the company has a market capitalization of $54.5 million.

AMDL is headquartered in Tustin, California. The operations of Jade, which AMDL acquired in September 2006, are in Shenzhen, Jiangxi and Jilin, China. Jade manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.




ChinaBio Today is a regular contributor to BioHealth Investor
____________
Stock Quote or
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Tue Jul 22, 2008 09:23AM
Hedge funds have made billions this year shorting the banks, [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.